Table 3

Risk of serious infant infections during the first year of life associated with biologics exposure in utero

Infant serious infections
ParameterOR (95% CI)
UnadjustedBiologics0.58 (0.18 to 1.85)
Model 1Biologics0.50 (0.16 to 1.60)
DMARDs/
immunosuppressants
1.07 (0.81 to 1.43)
Glucocorticoids1.46 (1.00 to 2.12)
Model 2Biologics0.56 (0.17 to 1.81)
DMARDs/
immunosuppressants
1.09 (0.81 to 1.45)
Glucocorticoids1.13 (0.77 to 1.66)
Female sex0.73 (0.60 to 0.89)
Multiparity1.56 (1.25 to 1.95)
Maternal antenatal visits0.97 (0.94 to 0.99)
Prior delivery with anomaly2.04 (0.98 to 4.26)
Prior delivery with
low birth weight
1.67 (1.05 to 2.64)
Prior premature delivery1.73 (1.21 to 2.47)
Maternal antidepressant use1.30 (0.97 to 1.75)
Maternal anxiolytics use1.66 (1.15 to 2.40)
Maternal rheumatoid
arthritis diagnosis
1.17 (0.93 to 1.47)
Maternal asthma diagnosis2.00 (1.18 to 3.39)
Apgar score at 1 min0.87 (0.83 to 0.92)
Neighbourhood income quintile0.91 (0.85 to 0.98)
Model 3
HDPS-matched cohort
Biologics0.49 (0.15 to 1.62)
  • DMARDs, disease-modifying antirheumatic drugs; HDPS, high-dimensional propensity score.